Fujita T, Noda H
Jpn Heart J. 1983 Jul;24(4):587-93. doi: 10.1536/ihj.24.587.
To evaluate the therapeutic efficacy of a new calcium antagonist, nicardipine in hypertension, the cardiovascular effects of chronic therapy were determined by echocardiography in 10 patients with uncomplicated mild to moderate hypertension. Significant declines were recorded in mean blood pressure (average; 11.7 +/- 0.8%) and total peripheral resistance (22.0 +/- 2.0%), accompanied by an increase in cardiac index (13.6 +/- 2.2%). In spite of the considerable degree of blood pressure reduction, heart rate and body weight were unchanged. The magnitude of the decline in total peripheral resistance was directly correlated to both the decrease in mean blood pressure (r = 0.701, p less than 0.02) and the increase in cardiac index (r = -0.953, p less than 0.01). These findings suggest that the hypotensive effect of this new calcium antagonist is due to peripheral vasodilation, and it appears to represent an effective adjunct for the treatment of mild to moderate hypertension.
为评估新型钙拮抗剂尼卡地平治疗高血压的疗效,采用超声心动图测定了10例无并发症的轻至中度高血压患者接受长期治疗后的心血管效应。平均血压(平均下降11.7±0.8%)和总外周阻力(下降22.0±2.0%)显著降低,同时心脏指数升高(升高13.6±2.2%)。尽管血压有相当程度的降低,但心率和体重未发生变化。总外周阻力下降幅度与平均血压降低(r = 0.701,p<0.02)及心脏指数升高(r = -0.953,p<0.01)均直接相关。这些发现提示,这种新型钙拮抗剂的降压作用是由于外周血管舒张,它似乎是治疗轻至中度高血压的一种有效辅助药物。